论文部分内容阅读
目的:探讨PDCD5在正常前列腺、良性前列腺增生(BPH)及前列腺癌(PCa)组织中的表达特点及其临床意义。方法:通过EnVision法对12例正常前列腺、22例前列腺增生及22例不同病理分级的PCa组织切片进行PDCD5免疫组织化学染色,采用人工阅片评分及计算机辅助染色强度判定2种方法对PDCD5在相应组织中的表达进行定性及定量分析。结果:PDCD5定性及定量检测结果分析显示:正常前列腺与BPH组织中PD-CD5表达无显著性差异(P>0.05),中低危组PCa(Glesaon评分≤7)及高危组PCa(Glesaon评分>7)组织中PD-CD5表达与正常前列腺与BPH均存在显著性差异(P<0.01),并且两组间PDCD5表达亦存在显著性差异(P<0.05)。结论:PDCD5在正常前列腺及BPH组织中近似地呈现较强的阳性表达。PDCD5在PCa组织中的表达较正常组织及BPH均有显著下降,并且随着PCa恶性程度上升,PDCD5的表达进一步下调,提示PDCD5可能在不同程度上参与了PCa发生、发展过程中腺细胞凋亡的调控。
Objective: To investigate the expression of PDCD5 in normal prostate, benign prostatic hyperplasia (BPH) and prostate cancer (PCa) and its clinical significance. Methods: 12 cases of normal prostate, 22 cases of benign prostatic hyperplasia and 22 cases of different pathological grades of PCa were enrolled in this study. PDCD5 immunohistochemical staining was performed by EnVision method. Two methods were used to evaluate the PDCD5 expression by Envision method. Tissue expression was qualitatively and quantitatively analyzed. Results: The results of qualitative and quantitative analysis of PDCD5 showed that there was no significant difference in the expression of PD-CD5 between normal prostate and BPH (P> 0.05), the PCa (Glesaon score≤7) and PCa (Glesaon score> (P <0.01). There was also significant difference in the expression of PDCD5 between the two groups (P <0.05) .7) There was a significant difference in the expression of PD-CD5 between normal prostate and BPH. Conclusion: PDCD5 presents approximately strong positive expression in normal prostate and BPH tissues. The expression of PDCD5 in PCa was significantly lower than that in normal tissues and BPH, and the expression of PDCD5 was further down-regulated with the increase of malignancy of PCa, suggesting that PDCD5 may be involved in the occurrence and development of PCa to varying degrees Regulation.